Mintz advised the underwriters in connection with Cogent Biosciences, Inc.’s concurrent public offerings of $345 million of common stock (the “Equity Offering”) and $230 million in aggregated principal amount of 1.625% convertible senior notes due 2031 (the “Convertible Notes Offering”).

J.P. Morgan, Jefferies, Leerink Partners, and Guggenheim Securities acted as joint-book running managers for the Equity Offering. LifeSci Capital acted as lead manager and Raymond James acted as co-manager for the Equity Offering. Jefferies and J.P. Morgan acted as joint book-running managers for the Convertible Notes Offering.

The Mintz capital markets team included William C. Hicks, John Rudy, Alok Choksi, Allyson Wilkinson, Samantha Silver, Jocelyn Sun, Christopher Kinney and Arieanna Sallie-Schmidt. Joanne Hawana provided regulatory advice, Edmund Koundakjian, PhD provided intellectual property advice, and Ari Feder advised on tax matters. Members of the Mintz team are based in the Boston, New York, San Diego, and Washington, DC offices.